Abstract 96P
Background
Archival storage of blood for single-cell (sc) RNA-Seq involves cryopreservation of peripheral blood mononuclear cells (PBMCs). However, this method excludes granulocytes and requires isolation of viable cells, whose transcriptomes may change due to processing time and technician handling. Hence, this method might overlook important data from temporal collection of clinical specimens. By contrast, blood collection in Qiagen PAXgene Blood RNA tubes is routinely practiced in medical sites without any special processing, and is completed with highly stabilized transcriptomes. Here, we present a novel method for single-nucleus (sn) RNA-Seq nuclei from frozen PAXgene blood as an alternative to PBMCs.
Methods
Fresh blood from healthy donors was collected, frozen in PAXgene tubes and processed by our novel method, which utilizes single-nucleus isolation and CRISPR-based strategy, yielding 3’RNA-Seq data via 10x Genomics’ Chromium platform. PBMCs from the same bloods were processed in parallel.
Results
Data quality evaluation revealed that PBMC transcript detection was higher than PAXgene, yet PAXgene RNA quality might exceed that of PBMCs. Unsupervised clustering was used to define cells and marker gene detection was used to assign cell types in PBMC and PAXgene data. Cell type subpopulations could be identified in PAXgene data, including central- and effector memory cells, and CD14+/16+ monocytes. Importantly, cells clustered based on cell type, indicating that sample biology was not masked by collection method. However, PAXgene specimens were distinct due to robust detection of granulocytes, including neutrophils (30-50% of blood cells). Proportions of PAXgene mononuclear cell populations were not significantly different from donor matched PBMCs. Results indicate that frozen PAXgene blood can be used to generate snRNA-Seq data that is comparable to PBMC scRNA-Seq, while also enabling transcriptomic characterization of granulocytes.
Conclusions
These findings provide preliminary evidence that PAXgene blood collection represents a simple, stable alternative to PBMC cryopreservation that could facilitate high quality, reproducible single-cell genomic profiling in clinical studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
AstraZeneca.
Funding
AsatraZeneca.
Disclosure
A. Rotem, O. Chaudhary, G. Duclos, P. Gathungu, M. Rao, R. Aguilar, L. Amir-Zilberstein, V. Shankarappa, C. Rands, X. Chen, E. Galery Harbolick, R. Halpin, M. Steinberg, J. Boland, M. Scaltriti, B. Dougherty: Financial Interests, Full or part-time Employment: AstraZeneca.
Resources from the same session
10P - Multivariate analysis of functional organoid assays predicts patient responses in the clinic for colorectal and pancreatic cancer
Presenter: Anna-Rose Gryspeert
Session: Poster session 07
11P - Therapeutic effects of MRTX1133 in KRAS G12D mutant appendiceal cancer: Insights from organoid and in vivo studies
Presenter: John Paul Shen
Session: Poster session 07
12P - STING-activable pyroptotic nanoparticles deliver GSDMDNT mRNA for in situ pancreatic cancer vaccination and immunotherapy
Presenter: Shiyi Shao
Session: Poster session 07
Resources:
Abstract
14P - EED inhibition renders vulnerability to immunotherapy by rewiring ceramide metabolism in pancreatic cancer
Presenter: Fan Chen
Session: Poster session 07
15P - TIGIT+ CD8+ T cells limit the efficacy of PD-L1 blockade plus chemoradiotherapy in MSS locally advanced rectal cancer via NECTIN2-TIGIT interplay
Presenter: Zhehui Zhu
Session: Poster session 07
16P - PTEN deficiency leads to colorectal cancer immune evasion via atypical Keap1/Nrf2 pathway
Presenter: RunKai Cai
Session: Poster session 07
17P - Breaking chemotherapy resistance in gastric adenocarcinoma: Immunogenic cell death induction by carbonic anhydrase IX targeting
Presenter: Elena Andreucci
Session: Poster session 07
18P - The role of CTNNA1 truncating variants in hereditary diffuse gastric cancer (HDGC)
Presenter: Silvana Lobo
Session: Poster session 07
19P - KSR1 as a therapeutic target for hepatocellular carcinoma with activated RAS-RAF-MEK-ERK signaling pathway
Presenter: HYUK MOON
Session: Poster session 07
20P - Preclinical characterization of FGFR1-4 variants of unknown significance
Presenter: Martin Ziegler
Session: Poster session 07